FALCON: a Multicenter Randomized Controlled Trial
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02558556 |
Recruitment Status : Unknown
Verified March 2019 by Maastricht University Medical Center.
Recruitment status was: Recruiting
First Posted : September 24, 2015
Last Update Posted : March 7, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Rationale: Several clinical feasibility studies have shown the potential benefit of near-infrared fluorescence (NIRF) imaging using indocyanine green (ICG) for enhanced and earlier biliary anatomy visualization during laparoscopic cholecystectomy with the aim to reduce the number of vascular and biliary injuries. Although the incidence of injuries is low (0.7%), the impact on patients in terms of morbidity, quality of life and costs are dramatic. The Critical View of Safety (CVS) technique is regarded as the safety valve in conventional laparoscopic cholecystectomy (CLC). It is hypothesized that standard application of near-infrared fluorescence imaging during laparoscopic cholecystectomy can be useful to obtain establishment of CVS (at least 5 minutes) earlier and with more certainty regarding visualization when compared to conventional laparoscopic imaging alone.
Study design: A multicenter randomized controlled trial with two study arms. Patients scheduled for an elective laparoscopic cholecystectomy will be recruited and randomized at the outpatient clinic (n = 308 total). One group will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy (NIRF-LC) and the other group will undergo conventional laparoscopic cholecystectomy (CLC).
Compared with standard care, patients in the NIRF-LC group have to receive one preoperative intravenous injection of ICG. This is the only additional minimally invasive action for the patient. Initially, patients participating in this study will not benefit from the application of NIRFC during the surgical procedure. The administration of ICG and the modified laparoscope itself are not related with any kind of additional risk for the patient.
Despite the encouraging results from several (pre)clinical feasibility studies, wide clinical acceptance of the routine use of ICG fluorescence laparoscopy is still lacking due to the absence of reliable and validated clinical data. A randomized clinical study is desirable to assess the potential added value of the NIRF imaging technique during laparoscopic cholecystectomy. Strong evidence in favor of routine implementation of this new imaging technique during laparoscopic cholecystectomy, will probably lead to worldwide routine application of the NIRF technique. Therewith long term sustainability of this research project is guaranteed.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cholecystolithiasis Cholecystitis | Device: Laparoscopic Fluorescence Imaging System (Karl Storz) Other: Indocyanine Green | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 308 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Near-infrared Fluorescence Cholangiography Assisted Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy (FALCON): a Multicenter Randomized Controlled Trial |
Study Start Date : | January 2016 |
Estimated Primary Completion Date : | December 2019 |
Estimated Study Completion Date : | July 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: NIRF-LC
This group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution. Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established. Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done. The complete procedure will be recorded on video. |
Device: Laparoscopic Fluorescence Imaging System (Karl Storz)
The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues. Other: Indocyanine Green Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
Other Name: ICG |
No Intervention: CLC
This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention. Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done. The complete procedure will be recorded on video. Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated. |
- time to identification of CVS [ Time Frame: at time of surgery ]change in time to identification of CVS
- time until identification of the transition of the cystic duct in the gallbladder during dissection of CVS [ Time Frame: at time of surgery ]change in time to identification
- visualization of CVS and visualization of the transition of the cystic duct and cystic artery in the gallbladder [ Time Frame: at time of surgery ]Are these structures actually visualized?
- total surgical time [ Time Frame: at time of surgery ]change in duration of surgery
- intraoperative bile leakage from the gallbladder or cystic duct [ Time Frame: at time of surgery ]change in number of intraoperative bile leakage from the gallbladder or cystic duct
- bile duct injury [ Time Frame: up to 90 days ]change in number of bile duct injuries
- postoperative length of hospital stay [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1-2 days ]change in length of hospital stay
- complications due to the injected contrast agent [ Time Frame: at time of surgery ]appearance of complications in intervention group
- conversion to open cholecystectomy [ Time Frame: at time of surgery ]change in number of conversions
- postoperative complications [ Time Frame: up to 90 days ]change in number of postoperative complications
- cost-minimisation: difference in costs between the treatment in both groups [ Time Frame: up to 90 days ]change in costs per patient

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Scheduled for elective laparoscopic cholecystectomy
- Normal liver and renal function
- No hypersensitivity for iodine or ICG
- Able to understand nature of the study procedures
- Willing to participate and with written informed consent
- Physical Status Classification: ASA I / ASA II
Exclusion Criteria:
- Age < 18 years
- Liver or renal insufficiency
- Known iodine or ICG hypersensitivity
- Pregnancy or breastfeeding
- Not able to understand nature of the study procedure
- Physical Status Classification: ASA III and above
- iv Heparin injection in the last 24 h; (LMWH not contraindicated)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02558556
Contact: Jacqueline van den Bos, MD | 0031613206302 | jacqueline.vanden.bos@mumc.nl |
Netherlands | |
Maastricht University Medical Center | Recruiting |
Maastricht, Limburg, Netherlands, 6229 | |
Contact: Jacqueline van den Bos, MD 0031613206302 jacqueline.vanden.bos@mumc.nl |
Principal Investigator: | Laurents PS Stassen, MD, PhD | Maastricht UMC |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Maastricht University Medical Center |
ClinicalTrials.gov Identifier: | NCT02558556 |
Other Study ID Numbers: |
NL47718.068.14 |
First Posted: | September 24, 2015 Key Record Dates |
Last Update Posted: | March 7, 2019 |
Last Verified: | March 2019 |
Laparoscopic cholecystectomy (LC) Indocyanine green (ICG) Near-Infrared Fluorescence Imaging (NIRF) Critical View of Safety (CVS) |
Cholecystitis Cholecystolithiasis Cholelithiasis Gallstones Gallbladder Diseases |
Biliary Tract Diseases Digestive System Diseases Calculi Pathological Conditions, Anatomical |